AMGNAmgenRunning, no new patients
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Chemotherapy-induced Thrombocytopenia
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 145 (final count)
- Started
- Feb 26, 2020
- Main results expected
- Mar 10, 2026
- Fully finished
- Feb 23, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of either a chemotherapy dose delay or reduction
Measured over: 48 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03937154 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC